Download presentation
Presentation is loading. Please wait.
Published byありあ たかひ Modified over 5 years ago
1
Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study Charles Kyung Min Lee, BS, Shufeng Li, MS, Duy Cong Tran, BS, Gefei Alex Zhu, MD, Jinah Kim, MD, PhD, Bernice Y. Kwong, MD, Anne Lynn S. Chang, MD Journal of the American Academy of Dermatology Volume 79, Issue 6, Pages (December 2018) DOI: /j.jaad Copyright © Terms and Conditions
2
Fig 1 Oncologic outcomes of patients with and without programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitor–associated dermatitis. A, Kaplan-Meier curves show progression-free survival after initiation of PD-1/PD-L1 inhibitor treatment. Patients who developed a PD-1/PD-L1 inhibitor–associated dermatitis (cases patients [blue]) had significantly longer progression-free survival than did patients with no PD-1/PD-L1 inhibitor–associated dermatitis (controls [red]) (P < .0001). B, Kaplan-Meier curves show overall survival after initiation of PD- 1/PD-L1 inhibitor treatment. Patients who developed a PD-1/PDL1 inhibitor–associated dermatitis (case patients [blue]) had significantly longer overall survival than did patients with no PD-1/PD-L1 inhibitor–associated dermatitis (controls [red]) (P = .0203). Journal of the American Academy of Dermatology , DOI: ( /j.jaad ) Copyright © Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.